Recent advances in the molecular understanding of glioblastoma

Journal of Neuro-Oncology

Volumn 108, Issue 1, 2012, Pages 11-27

  Bleeker, Fonnet E ^a   Molenaar, Remco J ^d   Leenstra, Sieger ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TweeSteden Hospital   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

(Epi)genetic; Glioblastoma; Molecular; Proteomic; Transcriptional

Indexed keywords

BEVACIZUMAB; ERLOTINIB; ETIRACETAM; MICRORNA; MICRORNA 124; MICRORNA 125; MICRORNA 128; MICRORNA 137; MICRORNA 15; MICRORNA 155; MICRORNA 181; MICRORNA 196; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 26; MICRORNA 296; MICRORNA 326; MICRORNA 34; MICRORNA 451; MICRORNA 7; PROTEIN INHIBITOR; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

CANCER GRADING; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CHROMOSOME ABERRATION; DEACETYLATION; DNA METHYLATION; EGFR GENE; ENZYME INHIBITION; EPIGENETICS; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMIC INSTABILITY; GLIOBLASTOMA; HISTOLOGY; HUMAN; IDH1 GENE; MGMT GENE; MOLECULAR GENETICS; ONCOGENE; OUTCOME ASSESSMENT; PHENOTYPE; PROTEOMICS; PTEN GENE; RECURRENT CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TP53 GENE; TUMOR CLASSIFICATION;

CENTRAL NERVOUS SYSTEM NEOPLASMS; EPIGENESIS, GENETIC; GLIOBLASTOMA; HUMANS; MUTATION; PROTEOMICS;

EID: 84860312386     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0793-0     Document Type: Review

References (126)

1. H Ohgaki P Kleihues 2007 Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 1445 1453 17456751 1:CAS:528:DC%2BD2sXlvFCns74%3D 10.2353/ajpath.2007.070011 (Pubitemid 47339290)
2. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 1:CAS:528:DC%2BD1MXlsVKhs74%3D 10.1016/S1470-2045(09) 70025-7
3. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 (Pubitemid 40349501)
4. D Krex B Klink C Hartmann A von Deimling T Pietsch M Simon M Sabel JP Steinbach O Heese G Reifenberger M Weller G Schackert 2007 Long-term survival with glioblastoma multiforme Brain 130 2596 2606 17785346 10.1093/brain/awm204 (Pubitemid 47511715)
5. EC Burton KR Lamborn BG Feuerstein M Prados J Scott P Forsyth S Passe RB Jenkins KD Aldape 2002 Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma Cancer Res 62 6205 6210 12414648 1:CAS:528:DC%2BD38XosF2msL4%3D (Pubitemid 35244472)
6. T Gorlia MJ van den Bent ME Hegi RO Mirimanoff M Weller JG Cairncross E Eisenhauer K Belanger AA Brandes A Allgeier D Lacombe R Stupp 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 29 38 18082451 10.1016/S1470-2045(07)70384-4
7. TCGAN 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061 1068 10.1038/nature07385 1:CAS:528:DC%2BD1cXht1yju77J
8. D Yin S Ogawa N Kawamata P Tunici G Finocchiaro M Eoli C Ruckert T Huynh G Liu M Kato M Sanada A Jauch M Dugas KL Black HP Koeffler 2009 High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray Mol Cancer Res 7 665 677 19435819 1:CAS:528:DC%2BD1MXmtFCisLk%3D 10.1158/1541-7786.MCR-08-0270
9. DW Parsons S Jones X Zhang JC Lin RJ Leary P Angenendt P Mankoo H Carter IM Siu GL Gallia A Olivi R McLendon BA Rasheed S Keir T Nikolskaya Y Nikolsky DA Busam H Tekleab LA Diaz Jr J Hartigan DR Smith RL Strausberg SK Marie SM Shinjo H Yan GJ Riggins DD Bigner R Karchin N Papadopoulos G Parmigiani B Vogelstein VE Velculescu KW Kinzler 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 1807 1812 18772396 1:CAS:528: DC%2BD1cXhtFCrtLrE 10.1126/science.1164382
10. D Hanahan RA Weinberg 2011 Hallmarks of cancer: the next generation Cell 144 646 674 21376230 1:CAS:528:DC%2BC3MXjsFeqtrk%3D 10.1016/j.cell.2011.02.013
11. SH Bigner R Bjerkvig OD Laerum 1985 DNA content and chromosomal composition of malignant human gliomas Neurol Clin 3 769 784 3001489 1:STN:280:DyaL28%2FptFOrsg%3D%3D (Pubitemid 16028837)
12. JA Maxwell SP Johnson RE McLendon DW Lister KS Horne A Rasheed JA Quinn F Ali-Osman AH Friedman PL Modrich DD Bigner HS Friedman 2008 Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma Clin Cancer Res 14 4859 4868 18676759 1:CAS:528:DC%2BD1cXpt1ejurk%3D 10.1158/1078-0432.CCR-07-4807
13. C Hunter R Smith DP Cahill P Stephens C Stevens J Teague C Greenman S Edkins G Bignell H Davies S O'Meara A Parker T Avis S Barthorpe L Brackenbury G Buck A Butler J Clements J Cole E Dicks S Forbes M Gorton K Gray K Halliday R Harrison K Hills J Hinton A Jenkinson D Jones V Kosmidou R Laman R Lugg A Menzies J Perry R Petty K Raine D Richardson R Shepherd A Small H Solomon C Tofts J Varian S West S Widaa A Yates DF Easton G Riggins JE Roy KK Levine W Mueller TT Batchelor DN Louis MR Stratton PA Futreal R Wooster 2006 A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy Cancer Res 66 3987 3991 16618716 1:CAS:528:DC%2BD28XjsFSlsbw%3D 10.1158/0008-5472.CAN-06-0127
14. HS Dahlback P Brandal TR Meling L Gorunova D Scheie S Heim 2009 Genomic aberrations in 80 cases of primary glioblastoma multiforme: pathogenetic heterogeneity and putative cytogenetic pathways Genes Chromosomes Cancer 48 908 924 19603525 1:CAS:528:DC%2BD1MXhtValsb7E 10.1002/gcc.20690
15. R Wiedemeyer C Brennan TP Heffernan Y Xiao J Mahoney A Protopopov H Zheng G Bignell F Furnari WK Cavenee WC Hahn K Ichimura VP Collins GC Chu MR Stratton KL Ligon PA Futreal L Chin 2008 Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development Cancer Cell 13 355 364 18394558 1:CAS:528:DC%2BD1cXkslSjtrc%3D 10.1016/j.ccr.2008.02.010 (Pubitemid 351454058)
16. R Beroukhim G Getz L Nghiemphu J Barretina T Hsueh D Linhart I Vivanco JC Lee JH Huang S Alexander J Du T Kau RK Thomas K Shah H Soto S Perner J Prensner RM Debiasi F Demichelis C Hatton MA Rubin LA Garraway SF Nelson L Liau PS Mischel TF Cloughesy M Meyerson TA Golub ES Lander IK Mellinghoff WR Sellers 2007 Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma Proc Natl Acad Sci USA 104 20007 20012 18077431 1:CAS:528:DC%2BD1cXhs1WmtQ%3D%3D 10.1073/pnas.0710052104
17. PJ Mulholland H Fiegler C Mazzanti P Gorman P Sasieni J Adams TA Jones JW Babbage R Vatcheva K Ichimura P East C Poullikas VP Collins NP Carter IP Tomlinson D Sheer 2006 Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme Cell Cycle 5 783 791 16582634 1:CAS:528:DC%2BD28XlvVCju7w%3D 10.4161/cc.5.7.2631
18. H Ohgaki P Dessen B Jourde S Horstmann T Nishikawa PL Di Patre C Burkhard D Schuler NM Probst-Hensch PC Maiorka N Baeza P Pisani Y Yonekawa MG Yasargil UM Lutolf P Kleihues 2004 Genetic pathways to glioblastoma: a population-based study Cancer Res 64 6892 6899 15466178 1:CAS:528:DC%2BD2cXotFalsrc%3D 10.1158/0008-5472.CAN-04-1337 (Pubitemid 39330996)
19. IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute BL Riggs S Horvath LM Liau WK Cavenee PN Rao R Beroukhim TC Peck JC Lee WR Sellers D Stokoe M Prados TF Cloughesy CL Sawyers PS Mischel 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 16282176 1:CAS:528: DC%2BD2MXht1SrtrrE 10.1056/NEJMoa051918 (Pubitemid 41609094)
20. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu A Misra JM Nigro H Colman L Soroceanu PM Williams Z Modrusan BG Feuerstein K Aldape 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 16530701 1:CAS:528:DC%2BD28XivFWjtL4%3D 10.1016/j.ccr.2006.02.019 (Pubitemid 43357943)
21. CE Pelloski E Lin L Zhang WK Yung H Colman JL Liu SY Woo AB Heimberger D Suki M Prados S Chang FG Barker III GN Fuller KD Aldape 2006 Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma Clin Cancer Res 12 3935 3941 16818690 1:CAS:528: DC%2BD28XmsValtLs%3D 10.1158/1078-0432.CCR-05-2202 (Pubitemid 44078078)
22. C Lopez-Gines R Gil-Benso R Ferrer-Luna R Benito E Serna J Gonzalez-Darder V Quilis D Monleon B Celda M Cerda-Nicolas 2010 New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile Mod Pathol 23 856 865 20305620 1:CAS:528: DC%2BC3cXmslSnsLg%3D 10.1038/modpathol.2010.62
23. M Weller J Felsberg C Hartmann H Berger JP Steinbach J Schramm M Westphal G Schackert M Simon JC Tonn O Heese D Krex G Nikkhah T Pietsch O Wiestler G Reifenberger A von Deimling M Loeffler 2009 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 5743 5750 19805672 1:CAS:528:DC%2BC3cXhtVWisbg%3D 10.1200/JCO.2009.23.0805
24. EA Maher C Brennan PY Wen L Durso KL Ligon A Richardson D Khatry B Feng R Sinha DN Louis J Quackenbush PM Black L Chin RA DePinho 2006 Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities Cancer Res 66 11502 11513 17114236 1:CAS:528:DC%2BD28Xht1KnsLrK 10.1158/0008-5472.CAN-06-2072 (Pubitemid 46009984)
25. N Holtkamp N Ziegenhagen E Malzer C Hartmann A Giese A von Deimling 2007 Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme Neuro Oncol 9 291 297 17504929 1:CAS:528:DC%2BD2sXpt1agsb8%3D 10.1215/15228517-2007-009 (Pubitemid 47169661)
26. K Ichimura AP Vogazianou L Liu DM Pearson LM Backlund K Plant K Baird CF Langford SG Gregory VP Collins 2008 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas Oncogene 27 2097 2108 17934521 1:CAS:528:DC%2BD1cXjslWjtrY%3D 10.1038/sj.onc.1210848 (Pubitemid 351442746)
27. AK Yadav JJ Renfrow DM Scholtens H Xie GE Duran C Bredel H Vogel JP Chandler A Chakravarti PA Robe S Das AC Scheck JA Kessler MB Soares BI Sikic GR Harsh M Bredel 2009 Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas JAMA 302 276 289 19602687 1:CAS:528:DC%2BD1MXosFyhsL8%3D 10.1001/jama.2009.1022
28. M Bredel DM Scholtens AK Yadav AA Alvarez JJ Renfrow JP Chandler IL Yu MS Carro F Dai MJ Tagge R Ferrarese C Bredel HS Phillips PJ Lukac PA Robe A Weyerbrock H Vogel S Dubner B Mobley X He AC Scheck BI Sikic KD Aldape A Chakravarti GRt Harsh 2011 NFKBIA deletion in glioblastomas N Engl J Med 364 627 637 21175304 1:CAS:528:DC%2BC3MXitFymtL0%3D 10.1056/NEJMoa1006312
29. S Veeriah C Brennan S Meng B Singh JA Fagin DB Solit PB Paty D Rohle I Vivanco J Chmielecki W Pao M Ladanyi WL Gerald L Liau TC Cloughesy PS Mischel C Sander B Taylor N Schultz J Major A Heguy F Fang IK Mellinghoff TAC Chan 2009 The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers Proc Natl Acad Sci USA 106 9435 9440 19478061 1:CAS:528:DC%2BD1MXot1Cgu74%3D
30. M Nakamura F Yang H Fujisawa Y Yonekawa P Kleihues H Ohgaki 2000 Loss of heterozygosity on chromosome 19 in secondary glioblastomas J Neuropathol Exp Neurol 59 539 543 10850866 1:CAS:528:DC%2BD3cXktlWrtbk%3D (Pubitemid 30368313)
31. C Bettegowda N Agrawal Y Jiao M Sausen LD Wood RH Hruban FJ Rodriguez DP Cahill R McLendon G Riggins VE Velculescu SM Oba-Shinjo SK Marie B Vogelstein D Bigner H Yan N Papadopoulos KW Kinzler 2011 Mutations in CIC and FUBP1 contribute to human oligodendroglioma Science 333 1453 1455 21817013 1:CAS:528:DC%2BC3MXhtFWqurnF 10.1126/science.1210557
32. RB Jenkins H Blair KV Ballman C Giannini RM Arusell M Law H Flynn S Passe S Felten PD Brown EG Shaw JC Buckner 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 17047046 1:CAS:528: DC%2BD28XhtVyiur3I 10.1158/0008-5472.CAN-06-1796 (Pubitemid 44672036)
33. H Zheng H Ying H Yan AC Kimmelman DJ Hiller AJ Chen SR Perry G Tonon GC Chu Z Ding JM Stommel KL Dunn R Wiedemeyer MJ You C Brennan YA Wang KL Ligon WH Wong L Chin RA DePinho 2008 p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation Nature 455 1129 1133 18948956 1:CAS:528:DC%2BD1cXht1yju7rE 10.1038/nature07443
34. GP Pfeifer P Hainaut 2011 Next-generation sequencing: emerging lessons on the origins of human cancer Curr Opin Oncol 23 62 68 21119514 10.1097/CCO.0b013e3283414d00
35. AJ Ekstrand N Sugawa CD James VP Collins 1992 Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails Proc Natl Acad Sci USA 89 4309 4313 1584765 1:CAS:528:DyaK38Xkt1Wntro%3D 10.1073/pnas.89.10. 4309
36. JC Lee I Vivanco R Beroukhim JH Huang WL Feng RM DeBiasi K Yoshimoto JC King P Nghiemphu Y Yuza Q Xu H Greulich RK Thomas JG Paez TC Peck DJ Linhart KA Glatt G Getz R Onofrio L Ziaugra RL Levine S Gabriel T Kawaguchi K O'Neill H Khan LM Liau SF Nelson PN Rao P Mischel RO Pieper T Cloughesy DJ Leahy WR Sellers CL Sawyers M Meyerson IK Mellinghoff 2006 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain PLoS Med 3 e485 17177598 10.1371/journal.pmed.0030485 1:CAS:528:DC%2BD2sXjsVGhuw%3D%3D (Pubitemid 46028511)
37. CB Knobbe J Reifenberger G Reifenberger 2004 Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas Acta Neuropathol 108 467 470 15517309 1:CAS:528:DC%2BD2cXhtVSitLrK 10.1007/s00401-004-0929-9 (Pubitemid 39534587)
38. C Greenman P Stephens R Smith GL Dalgliesh C Hunter G Bignell H Davies J Teague A Butler C Stevens S Edkins S O'Meara I Vastrik EE Schmidt T Avis S Barthorpe G Bhamra G Buck B Choudhury J Clements J Cole E Dicks S Forbes K Gray K Halliday R Harrison K Hills J Hinton A Jenkinson D Jones A Menzies T Mironenko J Perry K Raine D Richardson R Shepherd A Small C Tofts J Varian T Webb S West S Widaa A Yates DP Cahill DN Louis P Goldstraw AG Nicholson F Brasseur L Looijenga BL Weber YE Chiew A DeFazio MF Greaves AR Green P Campbell E Birney DF Easton G Chenevix-Trench MH Tan SK Khoo BT Teh ST Yuen SY Leung R Wooster PA Futreal MR Stratton 2007 Patterns of somatic mutation in human cancer genomes Nature 446 153 158 17344846 1:CAS:528:DC%2BD2sXisFygur0%3D 10.1038/nature05610 (Pubitemid 46398669)
39. FE Bleeker S Lamba S Leenstra D Troost T Hulsebos WP Vandertop M Frattini F Molinari M Knowles A Cerrato M Rodolfo A Scarpa L Felicioni F Buttitta S Malatesta A Marchetti A Bardelli 2009 IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors Hum Mutat 30 7 11 19117336 1:CAS:528:DC%2BD1MXivFygs7g%3D 10.1002/humu.20937
40. M Sanson Y Marie S Paris A Idbaih J Laffaire F Ducray S El Hallani B Boisselier K Mokhtari K Hoang-Xuan JY Delattre 2009 Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150 4154 19636000 1:CAS:528:DC%2BD1MXhtF2jtLrP 10.1200/JCO.2009.21.9832
41. S Nobusawa T Watanabe P Kleihues H Ohgaki 2009 IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 6002 6007 19755387 1:CAS:528:DC%2BD1MXhtF2ltbbL 10.1158/1078-0432.CCR- 09-0715
42. K Ichimura DM Pearson S Kocialkowski LM Backlund R Chan DT Jones VPC Collins 2009 IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas Neuro Oncol 11 341 347 19435942 1:CAS:528:DC%2BD1MXhtV2qur%2FF 10.1215/15228517-2009-025
43. J Balss J Meyer W Mueller A Korshunov C Hartmann A von Deimling 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 597 602 18985363 1:CAS:528:DC%2BD1cXhtlyhsbfN 10.1007/s00401-008-0455-2
44. H Yan DW Parsons G Jin R McLendon BA Rasheed W Yuan I Kos I Batinic-Haberle S Jones GJ Riggins H Friedman A Friedman D Reardon J Herndon KW Kinzler VE Velculescu B Vogelstein DD Bigner 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 19228619 1:CAS:528:DC%2BD1MXitFWru7o%3D 10.1056/NEJMoa0808710
45. FE Bleeker NA Atai S Lamba A Jonker D Rijkeboer KS Bosch W Tigchelaar D Troost WP Vandertop A Bardelli CJ Van Noorden 2010 The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma Acta Neuropathol 119 487 494 20127344 1:CAS:528:DC%2BC3cXjs1aju7Y%3D 10.1007/s00401-010-0645-6
46. S Zhao Y Lin W Xu W Jiang Z Zha P Wang W Yu Z Li L Gong Y Peng J Ding Q Lei KL Guan Y Xiong 2009 Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha Science 324 261 265 19359588 1:CAS:528:DC%2BD1MXktFals7g%3D 10.1126/science.1170944
47. L Dang DW White S Gross BD Bennett MA Bittinger EM Driggers VR Fantin HG Jang S Jin MC Keenan KM Marks RM Prins PS Ward KE Yen LM Liau JD Rabinowitz LC Cantley CB Thompson MG Vander Heiden SMC Su 2009 Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739 744 19935646 1:CAS:528:DC%2BD1MXhsVGlurzE 10.1038/nature08617
48. W Xu H Yang Y Liu Y Yang P Wang SH Kim S Ito C Yang MT Xiao LX Liu WQ Jiang J Liu JY Zhang B Wang S Frye Y Zhang YH Xu QY Lei KL Guan SM Zhao Y Xiong 2011 Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases Cancer Cell 19 17 30 21251613 1:CAS:528:DC%2BC3MXpvValsQ%3D%3D 10.1016/j.ccr.2010.12.014
49. T Watanabe S Nobusawa P Kleihues H Ohgaki 2009 IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 1149 1153 19246647 1:CAS:528:DC%2BD1MXksVOksLY%3D 10.2353/ajpath.2009.080958
50. ME Scheurer CJ Etzel M Liu R El-Zein GE Airewele B Malmer KD Aldape JS Weinberg WK Yung ML Bondy 2007 Aggregation of cancer in first-degree relatives of patients with glioma Cancer Epidemiol Biomarkers Prev 16 2491 2495 18006942 10.1158/1055-9965.EPI-07-0576 (Pubitemid 351196386)
51. JA Schwartzbaum Y Xiao Y Liu S Tsavachidis MS Berger ML Bondy JS Chang SM Chang PA Decker B Ding SJ Hepworth RS Houlston FJ Hosking RB Jenkins ML Kosel LS McCoy PA McKinney K Muir JS Patoka M Prados T Rice LB Robertson MJ Schoemaker S Shete AJ Swerdlow JL Wiemels JK Wiencke P Yang MRC Wrensch 2010 Inherited variation in immune genes and pathways and glioblastoma risk Carcinogenesis 31 1770 1777 20668009 1:CAS:528:DC%2BC3cXht1Ogtb%2FO 10.1093/carcin/bgq152
52. S El Hallani Y Marie A Idbaih M Rodero B Boisselier F Laigle-Donadey F Ducray JY Delattre M Sanson 2007 No association of MDM2 SNP309 with risk of glioblastoma and prognosis J Neurooncol 85 241 244 17568997 1:CAS:528: DC%2BD2sXhsVygt77O 10.1007/s11060-007-9416-1 (Pubitemid 350142512)
53. S Shete FJ Hosking LB Robertson SE Dobbins M Sanson B Malmer M Simon Y Marie B Boisselier JY Delattre K Hoang-Xuan S El Hallani A Idbaih D Zelenika U Andersson R Henriksson AT Bergenheim M Feychting S Lonn A Ahlbom J Schramm M Linnebank K Hemminki R Kumar SJ Hepworth A Price G Armstrong Y Liu X Gu R Yu C Lau M Schoemaker K Muir A Swerdlow M Lathrop M Bondy RS Houlston 2009 Genome-wide association study identifies five susceptibility loci for glioma Nat Genet 41 899 904 19578367 1:CAS:528:DC%2BD1MXotVCltrw%3D 10.1038/ng.407
54. M Wrensch RB Jenkins JS Chang RF Yeh Y Xiao PA Decker KV Ballman M Berger JC Buckner S Chang C Giannini C Halder TM Kollmeyer ML Kosel DH LaChance L McCoy BP O'Neill J Patoka AR Pico M Prados C Quesenberry T Rice AL Rynearson I Smirnov T Tihan J Wiemels P Yang JKC Wiencke 2009 Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility Nat Genet 41 905 908 19578366 1:CAS:528:DC%2BD1MXotVClt7w%3D 10.1038/ng.408
55. Y Liu S Shete CJ Etzel M Scheurer G Alexiou G Armstrong S Tsavachidis FW Liang M Gilbert K Aldape T Armstrong R Houlston F Hosking L Robertson Y Xiao J Wiencke M Wrensch U Andersson BS Melin MC Bondy 2010 Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival J Clin Oncol 28 2467 2474 20368557 1:CAS:528:DC%2BC3cXnsFOnt78%3D 10.1200/JCO.2009.26.6213
56. IHGSC 2004 Finishing the euchromatic sequence of the human genome Nature 431 931 945 10.1038/nature03001 1:CAS:528:DC%2BD2cXoslSlt7o%3D (Pubitemid 39434409)
57. A Lal AE Lash SF Altschul V Velculescu L Zhang RE McLendon MA Marra C Prange PJ Morin K Polyak N Papadopoulos B Vogelstein KW Kinzler RL Strausberg GJ Riggins 1999 A public database for gene expression in human cancers Cancer Res 59 5403 5407 10554005 1:CAS:528:DyaK1MXnt1Gjtbo%3D (Pubitemid 29526444)
58. V Santosh A Arivazhagan P Sreekanthreddy H Srinivasan B Thota MR Srividya M Vrinda S Sridevi BC Shailaja C Samuel KV Prasanna K Thennarasu A Balasubramaniam BA Chandramouli AS Hegde K Somasundaram P Kondaiah MR Rao 2010 Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma Cancer Epidemiol Biomarkers Prev 19 1399 1408 20501753 1:CAS:528:DC%2BC3cXntFCqtbs%3D 10.1158/1055-9965.EPI-09-1213
59. S Godard G Getz M Delorenzi P Farmer H Kobayashi I Desbaillets M Nozaki AC Diserens MF Hamou PY Dietrich L Regli RC Janzer P Bucher R Stupp N de Tribolet E Domany ME Hegi 2003 Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes Cancer Res 63 6613 6625 14583454 1:CAS:528:DC%2BD3sXosVGgurw%3D (Pubitemid 37322939)
60. JM Nigro A Misra L Zhang I Smirnov H Colman C Griffin N Ozburn M Chen E Pan D Koul WK Yung BG Feuerstein KD Aldape 2005 Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma Cancer Res 65 1678 1686 15753362 1:CAS:528:DC%2BD2MXitVOjs7c%3D 10.1158/0008-5472.CAN-04-2921 (Pubitemid 40478592)
61. A Hormigo B Gu S Karimi E Riedel KS Panageas MA Edgar MK Tanwar JS Rao M Fleisher LM DeAngelis EC Holland 2006 YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas Clin Cancer Res 12 5698 5704 17020973 1:CAS:528:DC%2BD28XhtVartbrE 10.1158/1078-0432.CCR-06-0181 (Pubitemid 44629598)
62. CL Tso P Shintaku J Chen Q Liu J Liu Z Chen K Yoshimoto PS Mischel TF Cloughesy LM Liau SF Nelson 2006 Primary glioblastomas express mesenchymal stem-like properties Mol Cancer Res 4 607 619 16966431 1:CAS:528: DC%2BD28XptlOhtr0%3D 10.1158/1541-7786.MCR-06-0005 (Pubitemid 44497214)
63. Y Lee AC Scheck TF Cloughesy A Lai J Dong HK Farooqi LM Liau S Horvath PS Mischel SF Nelson 2008 Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age BMC Med Genomics 1 52 18940004 10.1186/1755-8794-1-52 1:CAS:528:DC%2BD1MXhvVOks74%3D
64. SE Mir PC De Witt Hamer PM Krawczyk L Balaj A Claes JM Niers AA Van Tilborg AH Zwinderman D Geerts GJ Kaspers W Peter Vandertop J Cloos BA Tannous P Wesseling JA Aten DP Noske CJ Van Noorden T Wurdinger 2010 In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma Cancer Cell 18 244 257 20832752 1:CAS:528:DC%2BC3cXhtFGht7bJ 10.1016/j.ccr.2010.08.011
65. CL Tso WA Freije A Day Z Chen B Merriman A Perlina Y Lee EQ Dia K Yoshimoto PS Mischel LM Liau TF Cloughesy SF Nelson 2006 Distinct transcription profiles of primary and secondary glioblastoma subgroups Cancer Res 66 159 167 16397228 1:CAS:528:DC%2BD28XhsFWhsg%3D%3D 10.1158/0008-5472.CAN-05-0077 (Pubitemid 43166021)
66. M Vitucci DN Hayes CRC Miller 2011 Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy Br J Cancer 104 545 553 21119666 1:STN:280:DC%2BC3M7psV2rsg%3D%3D 10.1038/sj.bjc.6606031
67. LA Gravendeel MC Kouwenhoven O Gevaert JJ de Rooi AP Stubbs JE Duijm A Daemen FE Bleeker LB Bralten NK Kloosterhof B De Moor PH Eilers PJ van der Spek JM Kros PA Sillevis Smitt MJ van den Bent PJ French 2009 Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 9065 9072 19920198 1:CAS:528:DC%2BD1MXhsV2itLnO 10.1158/0008-5472.CAN-09-2307
68. A Li J Walling S Ahn Y Kotliarov Q Su M Quezado JC Oberholtzer J Park JC Zenklusen HAC Fine 2009 Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes Cancer Res 69 2091 2099 19244127 1:CAS:528: DC%2BD1MXisFSrurk%3D 10.1158/0008-5472.CAN-08-2100
69. M Bredel DM Scholtens GR Harsh C Bredel JP Chandler JJ Renfrow AK Yadav H Vogel AC Scheck R Tibshirani BI Sikic 2009 A network model of a cooperative genetic landscape in brain tumors JAMA 302 261 275 19602686 1:CAS:528: DC%2BD1MXosFyis7o%3D 10.1001/jama.2009.997
70. M de Tayrac M Aubry S Saikali A Etcheverry C Surbled F Guenot MD Galibert A Hamlat T Lesimple V Quillien P Menei J Mosser 2011 A 4-gene signature associated with clinical outcome in high-grade gliomas Clin Cancer Res 17 317 327 21224364 10.1158/1078-0432.CCR-10-1126 1:CAS:528:DC%2BC3MXmslyqsw%3D%3D
71. RG Verhaak KA Hoadley E Purdom V Wang Y Qi MD Wilkerson CR Miller L Ding T Golub JP Mesirov G Alexe M Lawrence M O'Kelly P Tamayo BA Weir S Gabriel W Winckler S Gupta L Jakkula HS Feiler JG Hodgson CD James JN Sarkaria C Brennan A Kahn PT Spellman RK Wilson TP Speed JW Gray M Meyerson G Getz CM Perou DNC Hayes 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 98 110 20129251 1:CAS:528:DC%2BC3cXkvFKgsL4%3D 10.1016/j.ccr.2009.12.020
72. M Esteller 2008 Epigenetics in cancer N Engl J Med 358 1148 1159 18337604 1:CAS:528:DC%2BD1cXjt1ahs7Y%3D 10.1056/NEJMra072067 (Pubitemid 351398489)
73. B Cadieux TT Ching SR VandenBerg JF Costello 2006 Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation Cancer Res 66 8469 8476 16951158 1:CAS:528:DC%2BD28XovF2isb4%3D 10.1158/0008-5472.CAN-06-1547 (Pubitemid 44449159)
74. RP Nagarajan JF Costello 2009 Epigenetic mechanisms in glioblastoma multiforme Semin Cancer Biol 19 188 197 19429483 1:CAS:528:DC%2BD1MXktV2isL0%3D 10.1016/j.semcancer.2009.02.005
75. R Martinez M Esteller 2010 The DNA methylome of glioblastoma multiforme Neurobiol Dis 39 40 46 20064612 1:CAS:528:DC%2BC3cXmtFahtLo%3D 10.1016/j.nbd.2009.12.030
76. M Nakamura Y Yonekawa P Kleihues H Ohgaki 2001 Promoter hypermethylation of the RB1 gene in glioblastomas Lab Invest 81 77 82 11204276 1:CAS:528:DC%2BD3MXht1Sht7w%3D 10.1038/labinvest.3780213 (Pubitemid 32108641)
77. M Nakamura E Ishida K Shimada M Kishi H Nakase T Sakaki N Konishi 2005 Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas Lab Invest 85 165 175 15592495 1:CAS:528: DC%2BD2MXhtFWgtLo%3D 10.1038/labinvest.3700223 (Pubitemid 40208920)
78. JK Wiencke S Zheng N Jelluma T Tihan S Vandenberg T Tamguney R Baumber R Parsons KR Lamborn MS Berger MR Wrensch DA Haas-Kogan D Stokoe 2007 Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro Oncol 9 271 279 17504928 1:CAS:528:DC%2BD2sXpt1agsLo%3D 10.1215/15228517-2007- 003 (Pubitemid 47169659)
79. A Etcheverry M Aubry M de Tayrac E Vauleon R Boniface F Guenot S Saikali A Hamlat L Riffaud P Menei V Quillien JC Mosser 2010 DNA methylation in glioblastoma: impact on gene expression and clinical outcome BMC Genomics 11 701 21156036 1:CAS:528:DC%2BC3cXhs1WqsbvP 10.1186/1471-2164-11-701
80. R Martinez F Setien C Voelter S Casado MP Quesada G Schackert M Esteller 2007 CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme Carcinogenesis 28 1264 1268 17272309 1:CAS:528:DC%2BD2sXnt1CmtLY%3D 10.1093/carcin/bgm014 (Pubitemid 47062686)
81. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 1:CAS:528:DC%2BD2MXit1Wktro%3D 10.1056/NEJMoa043331 (Pubitemid 40349502)
82. 6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival Clin Cancer Res 13 2606 2613 17473190 1:CAS:528:DC%2BD2sXkslOhtb4%3D 10.1158/1078-0432.CCR-06-2184 (Pubitemid 46788026)
83. I Zawlik S Vaccarella D Kita M Mittelbronn S Franceschi H Ohgaki 2009 Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study Neuroepidemiology 32 21 29 18997474 10.1159/000170088
84. M Christmann G Nagel S Horn U Krahn D Wiewrodt C Sommer B Kaina 2010 MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma Int J Cancer 127 2106 2118 20131314 1:CAS:528:DC%2BC3cXhtFSisrnP 10.1002/ijc.25229
85. 6-methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction BMC Cancer 11 35 21269507 10.1186/1471-2407-11-35
86. AA Brandes A Tosoni E Franceschi G Sotti G Frezza P Amista L Morandi F Spagnolli M Ermani 2009 Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status J Clin Oncol 8 1275 1279 10.1200/JCO.2008.19.4969 1:CAS:528:DC%2BD1MXktFKhsb4%3D
87. AA Brandes E Franceschi A Tosoni V Blatt A Pession G Tallini R Bertorelle S Bartolini F Calbucci A Andreoli G Frezza M Leonardi F Spagnolli M Ermani 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 18445844 10.1200/JCO.2007.14. 8163
88. H Noushmehr DJ Weisenberger K Diefes HS Phillips K Pujara BP Berman F Pan CE Pelloski EP Sulman KP Bhat RG Verhaak KA Hoadley DN Hayes CM Perou HK Schmidt L Ding RK Wilson D Van Den Berg H Shen H Bengtsson P Neuvial LM Cope J Buckley JG Herman SB Baylin PW Laird KC Aldape 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 510 522 20399149 1:CAS:528:DC%2BC3cXmslKqsr0%3D 10.1016/j.ccr.2010.03. 017
89. W Filipowicz SN Bhattacharyya N Sonenberg 2008 Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9 102 114 18197166 1:CAS:528:DC%2BD1cXnt1ensA%3D%3D 10.1038/nrg2290
90. C le Sage R Nagel DA Egan M Schrier E Mesman A Mangiola C Anile G Maira N Mercatelli SA Ciafre MG Farace RC Agami 2007 Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation EMBO J 26 3699 3708 17627278 10.1038/sj.emboj.7601790 1:CAS:528:DC%2BD2sXos1eqtb0%3D (Pubitemid 47236875)
91. T Wurdinger BA Tannous O Saydam J Skog S Grau J Soutschek R Weissleder XO Breakefield AMC Krichevsky 2008 miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells Cancer Cell 14 382 393 18977327 1:CAS:528:DC%2BD1cXhtlOjsLrN 10.1016/j.ccr.2008.10.005
92. SA Ciafre S Galardi A Mangiola M Ferracin CG Liu G Sabatino M Negrini G Maira CM Croce MG Farace 2005 Extensive modulation of a set of microRNAs in primary glioblastoma Biochem Biophys Res Commun 334 1351 1358 16039986 1:CAS:528:DC%2BD2MXntVOitb8%3D 10.1016/j.bbrc.2005.07.030 (Pubitemid 41074723)
93. Y Guan M Mizoguchi K Yoshimoto N Hata T Shono SO Suzuki Y Araki D Kuga A Nakamizo T Amano X Ma K Hayashi T Sasaki 2010 MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance Clin Cancer Res 16 4289 4297 20601442 1:CAS:528:DC%2BC3cXhtVajs7jM 10.1158/1078-0432.CCR-10-0207
94. J Godlewski MO Nowicki A Bronisz S Williams A Otsuki G Nuovo A Raychaudhury HB Newton EA Chiocca S Lawler 2008 Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal Cancer Res 68 9125 9130 19010882 1:CAS:528:DC%2BD1cXhtlOmt7zL 10.1158/0008-5472.CAN-08-2629
95. H Kim W Huang X Jiang B Pennicooke PJ Park MDC Johnson 2010 Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship Proc Natl Acad Sci USA 107 2183 2188 20080666 1:CAS:528: DC%2BC3cXhvFCiurw%3D 10.1073/pnas.0909896107
96. J Godlewski MO Nowicki A Bronisz G Nuovo J Palatini M De Lay J Van Brocklyn MC Ostrowski EA Chiocca SE Lawler 2010 MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells Mol Cell 37 620 632 20227367 1:CAS:528:DC%2BC3cXlt1KrsL4%3D 10.1016/j.molcel.2010.02.018
97. J Silber DA Lim C Petritsch AI Persson AK Maunakea M Yu SR Vandenberg DG Ginzinger CD James JF Costello G Bergers WA Weiss A Alvarez-Buylla JGC Hodgson 2008 miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells BMC Med 6 14 18577219 10.1186/1741-7015-6-14 1:CAS:528:DC%2BD1cXpvF2lurg%3D (Pubitemid 352003733)
98. B Kefas J Godlewski L Comeau Y Li R Abounader M Hawkinson J Lee H Fine EA Chiocca S Lawler B Purow 2008 microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma Cancer Res 68 3566 3572 18483236 1:CAS:528:DC%2BD1cXlvVOit78%3D 10.1158/0008-5472.CAN-07-6639
99. Y Li F Guessous Y Zhang C Dipierro B Kefas E Johnson L Marcinkiewicz J Jiang Y Yang TD Schmittgen B Lopes D Schiff B Purow RC Abounader 2009 MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes Cancer Res 69 7569 7576 19773441 1:CAS:528:DC%2BD1MXht1Skt7rF 10.1158/0008-5472.CAN- 09-0529
100. O Slaby R Lakomy P Fadrus R Hrstka L Kren E Lzicarova M Smrcka M Svoboda H Dolezalova J Novakova D Valik R Vyzula J Michalek 2010 MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients Neoplasma 57 264 269 20353279 1:CAS:528: DC%2BC3cXnt1yrsLk%3D 10.4149/neo-2010-03-264
101. B Kefas L Comeau DH Floyd O Seleverstov J Godlewski T Schmittgen J Jiang CG diPierro Y Li EA Chiocca J Lee H Fine R Abounader S Lawler BC Purow 2009 The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors J Neurosci 29 15161 15168 19955368 1:CAS:528:DC%2BD1MXhsFKltbvJ 10.1523/JNEUROSCI.4966-09.2009
102. JT Huse C Brennan D Hambardzumyan B Wee J Pena SH Rouhanifard C Sohn-Lee C le Sage R Agami T Tuschl ECC Holland 2009 The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo Genes Dev 23 1327 1337 19487573 1:CAS:528:DC%2BD1MXntlegsbc%3D 10.1101/gad.1777409
103. CZ Zhang JX Zhang AL Zhang ZD Shi L Han ZF Jia WD Yang GX Wang T Jiang YP You PY Pu JQ Cheng CSC Kang 2010 MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma Mol Cancer 9 229 20813046 10.1186/1476-4598-9-229 1:CAS:528:DC%2BC3cXhtFekur3J
104. K Asadi-Moghaddam EA Chiocca SE Lawler 2010 Potential role of miRNAs and their inhibitors in glioma treatment Expert Rev Anticancer Ther 10 1753 1762 21080802 1:CAS:528:DC%2BC3cXhsVCjs7jP 10.1586/era.10.168
105. RF Deighton R McGregor J Kemp J McCulloch IR Whittle 2010 Glioma pathophysiology: insights emerging from proteomics Brain Pathol 20 691 703 20175778 1:CAS:528:DC%2BC3cXpsVyhtbg%3D 10.1111/j.1750-3639.2010.00376.x
106. CK Park JH Jung SH Park HW Jung BK Cho 2009 Multifarious proteomic signatures and regional heterogeneity in glioblastomas J Neurooncol 94 31 39 19219580 10.1007/s11060-009-9805-8
107. Y Iwadate T Sakaida T Hiwasa Y Nagai H Ishikura M Takiguchi A Yamaura 2004 Molecular classification and survival prediction in human gliomas based on proteome analysis Cancer Res 64 2496 2501 15059904 1:CAS:528: DC%2BD2cXis1yjtbY%3D 10.1158/0008-5472.CAN-03-1254 (Pubitemid 38523905)
108. M Furuta RJ Weil AO Vortmeyer S Huang J Lei TN Huang YS Lee DA Bhowmick IA Lubensky EH Oldfield Z Zhuang 2004 Protein patterns and proteins that identify subtypes of glioblastoma multiforme Oncogene 23 6806 6814 15286718 1:CAS:528:DC%2BD2cXntFGnurc%3D 10.1038/sj.onc.1207770 (Pubitemid 39280012)
109. JM Stommel AC Kimmelman H Ying R Nabioullin AH Ponugoti R Wiedemeyer AH Stegh JE Bradner KL Ligon C Brennan L Chin RA DePinho 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 287 290 17872411 1:CAS:528:DC%2BD2sXhtFCjt7vP 10.1126/science.1142946 (Pubitemid 47574858)
110. J Du P Bernasconi KR Clauser DR Mani SP Finn R Beroukhim M Burns B Julian XP Peng H Hieronymus RL Maglathlin TA Lewis LM Liau P Nghiemphu IK Mellinghoff DN Louis M Loda SA Carr AL Kung TR Golub 2009 Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy Nat Biotechnol 27 77 83 19098899 1:CAS:528:DC%2BD1cXhsFajtbjI 10.1038/nbt.1513
111. PH Huang A Mukasa R Bonavia RA Flynn ZE Brewer WK Cavenee FB Furnari FM White 2007 Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma Proc Natl Acad Sci USA 104 12867 12872 17646646 1:CAS:528:DC%2BD2sXptVejtb8%3D 10.1073/pnas.0705158104 (Pubitemid 47255246)
112. J Lee S Kotliarova Y Kotliarov A Li Q Su NM Donin S Pastorino BW Purow N Christopher W Zhang JK Park HA Fine 2006 Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 391 403 16697959 1:CAS:528:DC%2BD28XltF2nsLk%3D 10.1016/j.ccr.2006.03.030 (Pubitemid 43668737)
113. A Li J Walling Y Kotliarov A Center ME Steed SJ Ahn M Rosenblum T Mikkelsen JC Zenklusen HA Fine 2008 Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas Mol Cancer Res 6 21 30 18184972 1:CAS:528:DC%2BD1cXhtFyisbk%3D 10.1158/1541-7786.MCR-07-0280 (Pubitemid 351378163)
114. ClinicalTrials.gov. A study of Avastin (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826?term= glioblastoma+bevacizumab&phase=2&rank=2. Accessed 21 October 2011
115. ClinicalTrials.gov. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00884741?term= glioblastoma+bevacizumab&phase=2&rank=1. Accessed 21 October 2011
116. MJ van den Bent AA Brandes R Rampling MC Kouwenhoven JM Kros AF Carpentier PM Clement M Frenay M Campone JF Baurain JP Armand MJ Taphoorn A Tosoni H Kletzl B Klughammer D Lacombe TC Gorlia 2009 Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 J Clin Oncol 27 1268 1274 19204207 10.1200/JCO.2008.17.5984 1:CAS:528:DC%2BD1MXktFKhsLc%3D
117. PD Brown S Krishnan JN Sarkaria W Wu KA Jaeckle JH Uhm FJ Geoffroy R Arusell G Kitange RB Jenkins JW Kugler RF Morton KM Rowland Jr P Mischel WH Yong BW Scheithauer D Schiff C Giannini JC Buckner 2008 Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 5603 5609 18955445 1:CAS:528:DC%2BD1MXmsVSrsg%3D%3D 10.1200/JCO.2008.18.0612
118. DA Haas-Kogan MD Prados T Tihan DA Eberhard N Jelluma ND Arvold R Baumber KR Lamborn A Kapadia M Malec MS Berger D Stokoe 2005 Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib J Natl Cancer Inst 97 880 887 15956649 1:CAS:528:DC%2BD2MXmtVahtrs%3D 10.1093/jnci/dji161 (Pubitemid 41417939)
119. DA Reardon A Desjardins JJ Vredenburgh S Gururangan AH Friedman JE Herndon 2nd J Marcello JA Norfleet RE McLendon JH Sampson HSC Friedman 2010 Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma J Neurooncol 96 219 230 19562254 1:CAS:528:DC%2BC3cXpsVSjtA%3D%3D 10.1007/s11060-009-9950-0
120. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon 2nd A Walker HSC Friedman 2009 Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 1262 1267 19204199 1:CAS:528:DC%2BD1MXktFKhsLY%3D 10.1200/JCO.2008.18.8417
121. GC Bobustuc CH Baker A Limaye WD Jenkins G Pearl NG Avgeropoulos SDC Konduri 2010 Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide Neuro Oncol 12 917 927 20525765 1:CAS:528:DC%2BC3cXhtVGrsbbP 10.1093/neuonc/noq044
122. JL Clarke FM Iwamoto J Sul K Panageas AB Lassman LM DeAngelis A Hormigo CP Nolan I Gavrilovic S Karimi LEC Abrey 2009 Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma J Clin Oncol 27 3861 3867 19506159 1:CAS:528:DC%2BD1MXhtFaitrrJ 10.1200/JCO.2008.20.7944
123. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 19114704 1:CAS:528: DC%2BD1MXjsVCjs7o%3D 10.1200/JCO.2008.16.3055
124. S Kunwar S Chang M Westphal M Vogelbaum J Sampson G Barnett M Shaffrey Z Ram J Piepmeier M Prados D Croteau C Pedain P Leland SR Husain BH Joshi RK Puri 2010 Phase III randomized trial of CED of IL13-PE38QQR vs. Gliadel wafers for recurrent glioblastoma Neuro Oncol 12 871 881 20511192 1:CAS:528: DC%2BC3cXpvFSltLw%3D 10.1093/neuonc/nop054
125. AB Madhankumar B Slagle-Webb X Wang QX Yang DA Antonetti PA Miller JM Sheehan JR Connor 2009 Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model Mol Cancer Ther 8 648 654 19276162 1:CAS:528:DC%2BD1MXjtVyjtrc%3D 10.1158/1535-7163.MCT-08-0853
126. J Clarke N Butowski S Chang 2010 Recent advances in therapy for glioblastoma Arch Neurol 67 279 283 20212224 10.1001/archneurol.2010.5